Loading
A phase 1/2 trial of Trastuzumab brengitecan in non-small-cell lung cancer and small-cell lung cancer, run by Sichuan Baili Pharmaceutical Co., Ltd., active and no longer recruiting.
A Study of BL-M07D1 in Patients With HER2-mutated, Locally Advanced or Metastatic Non-small-cell Lung Cancer is a phase 1/2 interventional study registered as NCT06114511 by Sichuan Baili Pharmaceutical Co., Ltd., with 78 participants enrolled, started 2024-04-24 and due to reach its primary completion in 2026-12. Interventions recorded: BL-M07D1. Conditions listed: Non-small Cell Lung Cancer. No results are recorded here; the registry entry is the source.
Shares Trastuzumab brengitecan, HER2-mutant non-small-cell lung cancer, SystImmune / Sichuan Biokin, Small-cell lung cancer.
Shares Trastuzumab brengitecan, HER2-mutant non-small-cell lung cancer, SystImmune / Sichuan Biokin, Small-cell lung cancer.
Shares HER2-mutant non-small-cell lung cancer, Topoisomerase-I inhibitors (and ADC payloads), Antibody-drug conjugate (ADC), Small-cell lung cancer.
Shares Trastuzumab brengitecan, SystImmune / Sichuan Biokin, Antibody-drug conjugate (ADC).
Shares HER2-mutant non-small-cell lung cancer, Topoisomerase-I inhibitors (and ADC payloads), Antibody-drug conjugate (ADC), Small-cell lung cancer.
Shares HER2-mutant non-small-cell lung cancer, Topoisomerase-I inhibitors (and ADC payloads), Antibody-drug conjugate (ADC), Small-cell lung cancer.
Shares Trastuzumab brengitecan, SystImmune / Sichuan Biokin, Antibody-drug conjugate (ADC).
Shares HER2-mutant non-small-cell lung cancer, Topoisomerase-I inhibitors (and ADC payloads), Antibody-drug conjugate (ADC), Small-cell lung cancer.